Outcome of Board Meeting held on 30.05.2025
Awaiting price reaction for this filing.
Uniworth International's Board approved audited results for FY25 on May 30, 2025, but the auditors (Khandelwal Ray & Co.) issued a Qualified Opinion on both standalone and consolidated statements. Total revenue from operations is NIL — the company explicitly states 'There is no business activities in the Company since long.' The standalone net loss for FY25 is Rs. 157.17 lakhs (similar to Rs. 156.03 lakhs loss in FY24), with negative EPS of Rs. (1.05). Net worth is deeply negative at Rs. (11,868.12) lakhs against total liabilities of Rs. 15,206.17 lakhs and total assets of Rs. 3,338.05 lakhs. Key audit qualifications (described as repetitive) flag non-provision for doubtful overdue export trade receivables of Rs. 3,010.57 lakhs, bank settlement/claims of Rs. 227.73 lakhs, miscellaneous advances of Rs. 52.70 lakhs, and a Rs. 5.12 lakhs investment in a sick company. On a consolidated basis, auditors were denied access to the subsidiary (Uniworth Biotech Limited), preventing verification of that investment.
This is a deeply negative filing for shareholders. The company has effectively zero operating revenue, is reporting consistent losses, and carries a hugely negative net worth indicating serious insolvency concerns. The qualified audit opinion flags over Rs. 3,290 lakhs of doubtful/unprovided assets, and going-concern uncertainty is embedded in the auditor's report. Expect continued stock price pressure and high risk profile; this is essentially a non-operating, financially distressed shell.